Výsledky vyhledávání - Scott, Rob

  • Zobrazuji výsledky 1 - 7 z 7
Upřesnit hledání
  1. 1
    Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism

    Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism Autor Chan, Dick C., Watts, Gerald F., Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Barrett, P. Hugh R.

    Vydáno 2018
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab

    Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab Autor Desai, Nihar R., Giugliano, Robert P., Wasserman, Scott M., Gibbs, John P., Liu, Thomas, Scott, Rob, Sabatine, Marc S.

    Vydáno 2017
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy

    Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hyperc... Autor Cho, Leslie, Rocco, Michael, Colquhoun, David, Sullivan, David, Rosenson, Robert S., Dent, Ricardo, Xue, Allen, Scott, Rob, Wasserman, Scott M, Stroes, Erik

    Vydáno 2014
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  4. 4
    HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

    HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Par... Autor Kohli, Payal, Ganz, Peter, Ma, Yifei, Scherzer, Rebecca, Hur, Sophia, Weigel, Bernard, Grunfeld, Carl, Deeks, Steven, Wasserman, Scott, Scott, Rob, Hsue, Priscilla Y.

    Vydáno 2016
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy

    Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hy... Autor Robinson, Jennifer G., Rogers, William J., Nedergaard, Bettina S., Fialkow, Jonathan, Neutel, Joel M., Ramstad, David, Somaratne, Ransi, Legg, Jason C., Nelson, Patric, Scott, Rob, Wasserman, Scott M., Weiss, Robert

    Vydáno 2014
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  6. 6
    PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role

    PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role Autor Raal, Frederick J., Giugliano, Robert P., Sabatine, Marc S., Koren, Michael J., Blom, Dirk, Seidah, Nabil G., Honarpour, Narimon, Lira, Armando, Xue, Allen, Chiruvolu, Padmaja, Jackson, Simon, Di, Mei, Peach, Matthew, Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Stein, Evan A.

    Vydáno 2016
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subjects 3 (GAUSS‐3) Trial

    Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐PCSK9 Antibody in Statin‐Intolerant Subj... Autor Nissen, Steven E., Dent‐Acosta, Ricardo E., Rosenson, Robert S., Stroes, Erik, Sattar, Naveed, Preiss, David, Mancini, G.B. John, Ballantyne, Christie M., Catapano, Alberico, Gouni‐Berthold, Ioanna, Stein, Evan A., Xue, Allen, Wasserman, Scott M., Scott, Rob, Thompson, Paul D.

    Vydáno 2016
    Získat plný text Získat plný text Získat plný text
    Text
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: